Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment options to hematologic malignancies.However,majority of patients with refractory or resistant hematologic malignancies can not achieve remission before transplantation.And the relapse rate of these patients after transplantation remains high obviously.